Carrier-free resveratrol nanoparticles: Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation

Ashok Kumar Jangid; Krunal Patel; Poonam Jain; Sunita Patel; Kanakaraju Medicherla; Deep Pooja; Hitesh Kulhari

doi:10.1016/j.matlet.2021.130340

Carrier-free resveratrol nanoparticles: Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation

Ashok Kumar Jangid
, Krunal Patel
, Poonam Jain
, Sunita Patel
, Kanakaraju Medicherla
, Deep Pooja
, Hitesh Kulhari

Department of Chemical and Biochemical Engineering

Central University of Gujarat
Andhra University
Royal Melbourne Institute of Technology University

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Resveratrol nanoparticles (RNP) formulation was prepared with 0.5% w/v of SDS and confirmed by TEM, XRD, DSC, XRD, FTIR and NMR. The prepared RNP were evaluated for physicochemical properties like solubility, stability, dissolution profile and partition coefficient. The anticancer activity of prepared RNP formulation was determined against HCT 116 human colorectal cancer cells by cell viability and apoptosis studies. An in vivo pharmacokinetic study in SD rats showed that, the AUC of the RNP was significantly higher (p < 0.0001) than the pure RSV. The plasma C_max was found to be 0.23 ± 0.02 μg/mL for RSV and 0.62 ± 0.09 μg/mL for RNP. An increase in AUC and C_max suggested that, the developed formulation was more bioavailable than the pure RSV.

Original language	English
Article number	130340
Journal	Materials Letters
Volume	302
DOIs	https://doi.org/10.1016/j.matlet.2021.130340
State	Published - 1 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bioavailability
Human colorectal cancer
Nanoparticle
Resveratrol

Access to Document

10.1016/j.matlet.2021.130340

Cite this

@article{6b75cb9214d04272bba69246951f2697,

title = "Carrier-free resveratrol nanoparticles: Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation",

abstract = "Resveratrol nanoparticles (RNP) formulation was prepared with 0.5\% w/v of SDS and confirmed by TEM, XRD, DSC, XRD, FTIR and NMR. The prepared RNP were evaluated for physicochemical properties like solubility, stability, dissolution profile and partition coefficient. The anticancer activity of prepared RNP formulation was determined against HCT 116 human colorectal cancer cells by cell viability and apoptosis studies. An in vivo pharmacokinetic study in SD rats showed that, the AUC of the RNP was significantly higher (p < 0.0001) than the pure RSV. The plasma Cmax was found to be 0.23 ± 0.02 μg/mL for RSV and 0.62 ± 0.09 μg/mL for RNP. An increase in AUC and Cmax suggested that, the developed formulation was more bioavailable than the pure RSV.",

keywords = "Bioavailability, Human colorectal cancer, Nanoparticle, Resveratrol",

author = "Jangid, \{Ashok Kumar\} and Krunal Patel and Poonam Jain and Sunita Patel and Kanakaraju Medicherla and Deep Pooja and Hitesh Kulhari",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.matlet.2021.130340",

language = "English",

volume = "302",

journal = "Materials Letters",

issn = "0167-577X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Carrier-free resveratrol nanoparticles

T2 - Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation

AU - Jangid, Ashok Kumar

AU - Patel, Krunal

AU - Jain, Poonam

AU - Patel, Sunita

AU - Medicherla, Kanakaraju

AU - Pooja, Deep

AU - Kulhari, Hitesh

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Resveratrol nanoparticles (RNP) formulation was prepared with 0.5% w/v of SDS and confirmed by TEM, XRD, DSC, XRD, FTIR and NMR. The prepared RNP were evaluated for physicochemical properties like solubility, stability, dissolution profile and partition coefficient. The anticancer activity of prepared RNP formulation was determined against HCT 116 human colorectal cancer cells by cell viability and apoptosis studies. An in vivo pharmacokinetic study in SD rats showed that, the AUC of the RNP was significantly higher (p < 0.0001) than the pure RSV. The plasma Cmax was found to be 0.23 ± 0.02 μg/mL for RSV and 0.62 ± 0.09 μg/mL for RNP. An increase in AUC and Cmax suggested that, the developed formulation was more bioavailable than the pure RSV.

AB - Resveratrol nanoparticles (RNP) formulation was prepared with 0.5% w/v of SDS and confirmed by TEM, XRD, DSC, XRD, FTIR and NMR. The prepared RNP were evaluated for physicochemical properties like solubility, stability, dissolution profile and partition coefficient. The anticancer activity of prepared RNP formulation was determined against HCT 116 human colorectal cancer cells by cell viability and apoptosis studies. An in vivo pharmacokinetic study in SD rats showed that, the AUC of the RNP was significantly higher (p < 0.0001) than the pure RSV. The plasma Cmax was found to be 0.23 ± 0.02 μg/mL for RSV and 0.62 ± 0.09 μg/mL for RNP. An increase in AUC and Cmax suggested that, the developed formulation was more bioavailable than the pure RSV.

KW - Bioavailability

KW - Human colorectal cancer

KW - Nanoparticle

KW - Resveratrol

UR - https://www.scopus.com/pages/publications/85108990328

U2 - 10.1016/j.matlet.2021.130340

DO - 10.1016/j.matlet.2021.130340

M3 - Article

AN - SCOPUS:85108990328

SN - 0167-577X

VL - 302

JO - Materials Letters

JF - Materials Letters

M1 - 130340

ER -

Carrier-free resveratrol nanoparticles: Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this